Neumora Therapeutics Inc

NMRA

Company Profile

  • Business description

    Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

  • Contact

    260 Arsenal Place
    Suite 1
    WatertownMA02472
    USA

    T: +1 857 760-0900

    https://www.neumoratx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    96

Stocks News & Analysis

stocks

Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?

From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.
stocks

ASX energy share remains cheap despite strong outlook

Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.
stocks

Moated AI-proof tech play hiding in the ASX 100

ChatGPT and large language models should be a tailwind for this company.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,006.4019.00-0.21%
CAC 408,157.8269.50-0.84%
DAX 4024,128.9826.47-0.11%
Dow JONES (US)49,230.7179.61-0.16%
FTSE 10010,379.0877.93-0.75%
HKSE25,978.0762.870.24%
NASDAQ24,836.60398.101.63%
Nikkei 22559,716.18575.950.97%
NZX 50 Index12,874.949.99-0.08%
S&P 5007,165.0856.680.80%
S&P/ASX 2008,786.5012.10-0.14%
SSE Composite Index4,079.9013.35-0.33%

Market Movers